VRCA Stock — Verrica Pharmaceuticals Inc.: Cash, EV, Pipeline

What they do

We are a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Currently, our commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need.

Source: 10-K FY2025 via SEC EDGAR

Share price

$3.19

Market cap

$54.8M

Cash

$11.2M

Enterprise value

$43.6M

Balance sheet

Cash	$11.2M
Debt	$0.0M
Net cash	$11.2M
Enterprise value	$43.6M
Basic shares	17.2M shares
Fully diluted shares	29.4M shares
Fully diluted market cap	$93.9M
Cash per share	$0.65
Quarterly burn	$9.3M
Cash runway	1.2 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

17.2M

Pre-funded warrants

9.4M

Options

2.9M

RSUs

—

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

—

FDSO

29.4M

Cap table as of 2026-07-31.

Price history

Loading VRCA daily closes…

Loading price history…

Next catalyst

YCANTH (VP-102) · Est. Mar 31, 2027 · PCD + 6 wks · guided in 5 mo

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Mar 31, 2027 in 5 mo PCD + 6 wks · Mar 31–Mar 31	YCANTH (VP-102) Pivotal Phase 3 COVE-2 trial of YCANTH (VP-102) in common warts: topline data	Phase 3	common warts: data	Q1 2027
GUIDEDEst. Aug 31, 2027 in 10 mo PCD + 6 wks · Aug 31–Aug 31	YCANTH (VP-102) Pivotal Phase 3 COVE-3 trial of YCANTH (VP-102) in common warts: topline data	Phase 3	common warts: data	mid-2027

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

YCANTH

Approved · Active Modality: topical

Aliases VP-102, TO-208, cantharidin 0.7% topical solution

Partnerships Torii/Shionogi (Japan; exclusive license for cantharidin products for molluscum and common warts; YCANTH/TO-208 approved in Japan Sep 2025, launched Feb 2026)

Indications

Molluscum contagiosum (Approved)
Common warts (Phase 2)

Status note First FDA-approved product for molluscum (Jul 2023, ages 2+); commercially launched in U.S. Aug 2023. Phase 2 COVE-1 in common warts completed; Type C meeting held. Cash of $11.2M at Jun 30, 2026 with $12.5M credit facility (PD Credit Agreement, Aug 2026).

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	VP-102
Lead indication	Common Warts
Lead phase	Phase 3
Active trials	3

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07637734	Phase 3	Recruiting	Sponsor	VRCA	—	Common Warts; Common Warts (Verruca Vulgaris); Human Papilloma Virus (HPV)	—
NCT07246590	Phase 3	Recruiting	Sponsor	VRCA	—	Common Warts; Common Warts (Verruca Vulgaris); Human Papilloma Virus (HPV)	—
NCT07457918	Phase 3	Recruiting	Sponsor	VRCA	—	Common Warts (Verruca Vulgaris); Common Warts; Human Papilloma Virus (HPV)	Q1 2027 Est. Mar 31, 2027 · PCD + 6 wks (Mar 31-Mar 31) mid-2027 Est. Aug 31, 2027 · PCD + 6 wks (Aug 31-Aug 31)

Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 3 active trials for Verrica Pharmaceuticals Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
DAFNA Capital	23,750	-129,962	0.03%	2026-08-14
Stonepine Capital	0	-99,735	0.00%	2026-08-17

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

VRCA — Verrica Pharmaceuticals Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

VRCA — Verrica Pharmaceuticals Inc.